生长因子受体信号通路在乳腺癌内分泌治疗耐药中的研究进展  

Progression of Growth Factor Receptor Signaling Pathway in Endocrine-Resistant Breast Cancer

作　　者：李聪[1] 李志高[1] 任延律[1] 庞达[1] 程绍强[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院乳腺外科,黑龙江哈尔滨150040

出　　处：《中国普外基础与临床杂志》2016年第5期626-630,共5页Chinese Journal of Bases and Clinics In General Surgery

基　　金：黑龙江省自然科学基金项目(编号:H2015051)~~

摘　　要：目的总结生长因子受体信号通路在乳腺癌内分泌治疗耐药中的研究进展。方法利用Pub Med搜索相关文献,总结生长因子受体信号通路在乳腺癌内分泌治疗耐药中的作用机制。结果生长因子受体信号通路与雌激素受体信号通路的串话作用参与乳腺癌内分泌治疗耐药过程,阻断生长因子受体信号通路有助于克服内分泌治疗耐药。许多临床试验结果表明靶向阻断生长因子受体信号通路的药物联合内分泌治疗药物可显著提高患者的生存率。结论靶向生长因子受体信号通路的药物在乳腺癌治疗中具有良好前景。Objective To summarize progression of growth factor receptor（GFR） signaling pathway in endocrineresistant breast cancer. Method Literatures about mechanisms of GFR signaling pathway in the development of endocrineresistant breast cancer were reviewed. Results The crosstalk between GFR and estrogen receptor（ER） signaling pathway had been reported to be involved in the development of endocrine-resistant breast cancer. Interrupting this signaling pathway could overcome endocrine therapy resistance. Many clinical trails had shown that the utilizing endocrine therapy combined with GFR inhibitors could obviously increase the survival rate of patients with breast cancer. Conclusion Several agents targeting GFR signaling pathways show a great potential for treatment of patients with breast cancer.

关 键 词：乳腺癌 内分泌治疗 耐药 生长因子受体 雌激素受体 

分 类 号：R737.9[医药卫生—肿瘤]